Table 1. Characteristics of the included RCT studies.
| Author (year) | Journal | Location | Medication | Type of patient | Primary endpoint | No. of eyes | Sex (male/female) | Age | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaucoma | NSAID | NSAID | Control | NSAID | Control | ||||||
| C. Costagliola (2005) | Exp Eye Res | Italy | Timolol/ Latanoprost | Diclofenac | POAGa | 10 weeks | 32 | 32 | 16/16 | 16/16 | 55.4±5.11 |
| T. Chiba (2006) | Br J Ophthalmol | Japan | Latanoprost | Bromfenac | POAG/ OHb | 18 weeks | 13 | 13 | 6/7 | 6/7 | 65.2±8.8 |
| C. Costagliola (2008) | Curr Eye Res | Italy | Latanoprost | Ketorolac | POAG | 1 day | 16 | 16 | 9/7 | 9/7 | 59.45±4.55 |
| R. Sorkhabi (2011) | J Glaucoma | Iran | Latanoprost | Diclofenac | POAG | 2 weeks | 22 | 22 | 12/10 | 12/10 | 60.55±9.46 |
| E. Turan-Vural (2011) | Ophthalmologica | Turkey | Latanoprost/Travoprost/ Brimatoprost | Ketorolac | POAG/ Pseudo-exfoliation glaucoma | 2 weeks | 30 | 30 | 15/15 | 15/15 | 60.8±11.5 |
| P. Özyol (2016) | J Glaucoma | Turkey | Latanoprost/ Travoprost/ Brimatoprost | Nepafenac | POAG | 2 weeks | 35 | 35 | 20/15 | 20/15 | 60.28±7.51 |
| Z. Simin (2018) | J Ophthalmol | China | Latanoprost | Pranoprofen | POAG | 10weeks | 24 | 24 | 13/11 | 10/14 | 32.4±4.7 |
aPOAG = primary open angle glaucoma
bOH = ocular hypertension